Skip to Content
  • Previous Rank375
  • Revenues ($M)9,703
  • Revenue Percent Change40%
  • Profits ($M)2,935
  • Profits Percent Change57.6%
  • Market Value (as of March 31, 2015)99,064

The biotechnology company discovers and manufactures treatments for autoimmune disorders, neurodegenerative diseases and hemophilia.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
George A. Scangos
Industry
Pharmaceuticals
Sector
Health Care
HQ Location
Cambridge, MA
Websitehttp://www.biogen.com
Years on List6

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)9,70340%
Profits ($M)2,93557.6%
Total Stockholder Equity10,809-
Employees7,550-
Market Value (as of March 31, 2015)99,064-

Profit Ratios

Profit as % of Revenues30.2%
Profits as % of Assets20.5%
Profits as % of Stockholder Equity27.2%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)12.37
EPS % Change (from 2013)58.4%
EPS % Change (5 year annual rate)29.9%
EPS % Change (10 year annual rate)67.8%

Total Return

Total Return to Investors (2014)21.4%
Total Return to Investors (5 year, annualized)44.7%
Total Return to Investors (10 year, annualized)17.7%